Granuloma annulare

• Published in: Hautarzt 2015-11, Vol.66 (11), p.867-75; quiz 876-7
• Main Authors: Butsch, F, Weidenthaler-Barth, B, von Stebut, E
• Format: Article
• Language: ger
• Subjects: Adrenal Cortex Hormones - administration & dosage; Anti-Inflammatory Agents - administration & dosage; Diagnosis, Differential; Evidence-Based Medicine; Granuloma Annulare - drug therapy; Granuloma Annulare - pathology; Humans; Immunologic Factors - administration & dosage; Treatment Outcome
• ISSN: 1432-1173
• DOI: 10.1007/s00105-015-3704-z

Granuloma annulare is a benign, chronic inflammatory skin disease. Its pathogenesis is still unclear, but reports on infections as a trigger can be found. In addition, some authors reported an association with other systemic disease, e.g., cancer, trauma, and diabetes mellitus; however, these have not been verified. The clinical picture of granuloma annulare ranges from the localized form predominantly at the extremities to disseminated, subcutaneous, or perforating forms. Diagnosis is based on the typical clinical presentation which may be confirmed by a biopsy. Histologically, necrobiotic areas within granulomatous inflammation are typical. The prognosis of the disease is good with spontaneous resolution being frequently observed, especially in localized forms. Disseminated manifestations tend to persist longer, and recurrences are reported. When choosing between different therapeutic options, the benign disease character versus the individual degree of suffering and the potential therapy side effects must be considered. For local treatment, topical application of corticosteroids is most common. Disseminated forms can be treated systemically with corticosteroids for several weeks; alternatively, dapsone, hydroxychloroquine, retinoids, fumaric acid, cyclosporine, and anti-TNFα appear to be effective.